Form 4: Ultragenyx CEO Emil Kakkis Sells Shares After Stock Grant

Ultragenyx CEO Emil Kakkis disposed of 8,273 shares of common stock at $50 per share after receiving a grant of 20,000 shares.

Summary

• Emil Kakkis, the President and CEO of Ultragenyx Pharmaceutical Inc., reported changes in his beneficial ownership of the company's stock.
• On December 9, 2024, Kakkis received 20,000 shares of common stock as a grant.
• On December 10, 2024, Kakkis sold 8,273 shares of common stock at a price of $50 per share.
• Following these transactions, Kakkis's indirect ownership through the Emil Kakkis and Jenny Soriano Living Trust is 2,195,712 shares.
• The report also includes previously reported shares of common stock underlying RSUs granted to Kakkis, which are subject to vesting conditions, and 8 shares acquired under the company's Employee Stock Purchase Plan on October 31, 2024.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions. While the sale of shares by the CEO could be seen as slightly negative, it's a common occurrence and doesn't necessarily indicate a major shift in sentiment.

Negatives

• The sale of 8,273 shares by the CEO could be interpreted negatively by some investors.

Risks

• Executive stock sales can sometimes be perceived as a lack of confidence in the company's future performance, potentially impacting investor sentiment.

Industry Context

This is a routine SEC Form 4 filing, which is common for executives of publicly traded companies when they buy or sell company stock. These filings are closely watched by investors for insights into management's view of the company's prospects.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, and the reporting of these transactions via SEC Form 4 is standard practice.
• The sale of shares by a CEO is not unusual, but the timing and size of the transaction can be scrutinized by investors.
• Comparable companies in the biotech sector also have executives who regularly trade company stock, and these transactions are similarly reported.

Stakeholder Impact

• Shareholders may react to the CEO's stock sale, potentially impacting the stock price.

Key Dates

Keywords

Ultragenyx, Emil Kakkis, stock sale, insider trading, share ownership, executive compensation, RARE